Suchergebnisse - "Metallidis, Symeon"

PubPharm (7)

1

The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum : will gliflozins have a different fate than statins?

enthalten in: Expert opinion on pharmacotherapy | 2023

von Koufakis, T. | Tsimihodimos, V. | Metallidis, S. | +2

2

Looking deeper into the findings of DARE-19 : Failure or an open door to future success?

enthalten in: Pharmacological research | 2021

von Koufakis, T. | Maltese, G. | Metallidis, S. | +2

CommentOn: Inflammopharmacology. 2021 Feb;29(1):269-279. - PMID 32564182

3

Sodium-glucose co-transporter 2 inhibitors in COVID-19 : meeting at the crossroads between heart, diabetes and infectious diseases

enthalten in: International journal of clinical pharmacy | 2021

von Koufakis, T. | Pavlidis, A. | Metallidis, S. | +1

4

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

enthalten in: International journal of clinical pharmacy | 2021

von Koufakis, T. | Pavlidis, A. | Metallidis, S. | +1

5

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

enthalten in: International journal of clinical pharmacy | 2021

von Koufakis, T. | Pavlidis, A. | Metallidis, S. | +1

6

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

enthalten in: Pharmacy world & science | 2021

von Koufakis, T. | Pavlidis, A. | Metallidis, S. | +1

7

Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic : Is the Benefit to Risk Ratio Still Favorable?

enthalten in: Journal of diabetes science and technology | 2020

von Koufakis, T. | Metallidis, S. | Zebekakis, P. | +2

1
[1]